Pharma BD Deal Intelligence
Ranks computed across 828 graded deals (Critic + Outcome Score both present).
Hoechst AG agreed to acquire Marion Merrell Dow for $7.1 billion, purchasing all outstanding shares at $25.75 per share, creating Hoechst Marion Roussel with…
The Federal Trade Commission reviewed Hoechst AG's $7.1 billion acquisition of Marion Merrell Dow, requiring divestitures to restore competition for four drugs…
Source summaries from our enrichment pipeline; follow links for originals.
All 3 sources with sentiment breakdown →
Hoechst AG acquired the remaining shares of Marion Merrell Dow it did not already own for $7.1 billion ($25.75/share). The deal was structured in two steps: first acquiring Dow Chemical's 71% stake (~$5.1B), then the remaining public float. The combined entity became Hoechst Marion Roussel.
| Deal | Year | Value | Outcome |
|---|---|---|---|
| Hoechst AG / Marion Merrell Dow Inc. (this deal) | 1995 | $7.1B | 73 |
| Pfizer Inc. / FoldRx Pharmaceuticals | 2010 | — | 99 |
| Abbott Laboratories / Knoll Pharmaceuticals (BASF Pharma) | 2000 | $6.9B | 95 |
| Astra AB / Zeneca Group plc | 1998 | $35.0B | 94 |
| Merck & Co. Inc. / Acceleron Pharma Inc. | 2021 | $11.5B | 90 |
| Johnson & Johnson / Actelion Ltd | 2017 | $30.0B | 90 |
| Eli Lilly and Company / Boehringer Ingelheim GmbH | 2011 | $444M | 89 |
← Browse all deals · How we score deals
More: 1995 deals · Cardiovascular deals